Diabetes & Endocrinology Clinical Trials Update: Week 27, 2026

Published July 3, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Established Onset Type 1 Diabetes Treated With Human Anti-Thymocyte Globulin [h-ATG]) Study

This Phase 3 trial is testing an immunotherapy drug called SAB-142 for people aged 5 to 40 with type 1 diabetes. The goal is to preserve the insulin-producing cells in the pancreas, which may slow down the progression of the disease. If successful, this could offer a new treatment option beyond the standard care currently available, providing hope for better management of type 1 diabetes.

A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

This Phase 3 trial is evaluating tirzepatide, a once-weekly injection, in adolescents who are overweight or have obesity along with weight-related health problems. The treatment aims to help reduce body weight and improve overall health in young people facing these challenges. Results are expected after about 90 weeks, which could lead to new options for managing obesity in youth.

A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes

This Phase 3 study is testing enicepatide, a new drug that targets two receptors involved in metabolism, in adults who are overweight or have obesity, with or without type 2 diabetes. The hope is that enicepatide will assist in weight management and improve health outcomes for people with these conditions. The trial is currently recruiting in China and plans to evaluate effects after one year of treatment.

Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity

This Phase 3 trial is exploring how semaglutide, a medication already used for obesity, affects brain function related to appetite and eating behaviors in both youth and adults. Understanding these effects could help tailor obesity treatments based on age, potentially making them more effective. The study is recruiting in the United States and includes 120 participants.

Dual vs Triple Lipid-Lowering Therapy in Type 2 Diabetes Mellitus Patients With Elevated LDL Cholesterol

This Phase 4 study compares two different approaches to lowering bad cholesterol in adults with type 2 diabetes and high LDL cholesterol. It looks at whether adding a drug called bempedoic acid to the treatment plan safely improves cholesterol control. The trial is recruiting in Pakistan and results will be available after six months, which may inform better strategies for managing heart risks in diabetes.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.